Search results for "Infusion solution"

showing 7 items of 7 documents

Physicochemical stability of cabazitaxel containing premix solution and diluted infusion solutions

2015

Objectives This study was conducted to investigate the extended physicochemical stability of cabazitaxel containing premix solution and diluted infusion solutions in either 0.9% sodium chloride (NaCl) or 5% glucose (G5) vehicle solution. Methods A stability indicating, reverse phase, high performance liquid chromatography assay with ultraviolet detection was developed and validated. Premix solutions of cabazitaxel were prepared in the original vials. Infusion solutions were prepared in prefilled polypropylene/polyethylene (PP/PE) infusion bags (0.9% NaCl, G5) to achieve the recommended minimum and maximum cabazitaxel concentrations (0.1 mg/mL, 0.26 mg/mL). Test solutions were stored refrige…

Polypropylenemedicine.medical_specialtyChromatographyInfusion solutionChemistrySodiumchemistry.chemical_elementPolyethyleneHigh-performance liquid chromatographySurgerychemistry.chemical_compoundCabazitaxelmedicinePhysical stabilityGeneral Pharmacology Toxicology and PharmaceuticsQuantitative analysis (chemistry)medicine.drugEuropean Journal of Hospital Pharmacy
researchProduct

Plasticizer extraction of Taxol infusion solution from various infusion devices.

1996

Taxol solution extracts the plasticizer DEHP (di(2-ethylhexyl)phthalate) from polyvinyl chloride (PVC) materials. In order to minimize patient exposure to DEHP, Taxol solutions should be prepared and administered in PVC-free materials. Particulate matter may form in Taxol infusion solution over time, so that in-line filtration with microporous membranes not greater than 0.22 microns is advisable. The purpose of this study was to evaluate the suitability of various administration- and in-line filter-sets for Taxol application. The extent of leached DEHP was determined using a Reversed Phase HPLC assay specific for DEHP. The four tested administration-sets, labeled as PVC-free, were all found…

endocrine systemPaclitaxelDrug StoragePharmaceutical Sciencemacromolecular substancesPharmacyToxicologylaw.inventionchemistry.chemical_compoundlawPlasticizersMicroporous membranesDiethylhexyl PhthalateHumansPharmacology (medical)Infusions IntravenousFiltrationChromatography High Pressure LiquidDrug PackagingPharmacologyChromatographyInfusion solutionorganic chemicalsExtraction (chemistry)PhthalatePlasticizerGeneral MedicineReversed-phase chromatographyAntineoplastic Agents PhytogenicPolyvinyl chloridechemistryPharmacy worldscience : PWS
researchProduct

Physicochemical stability of irinotecan injection concentrate and diluted infusion solutions in PVC bags

2000

Purpose. To determine the physicochemical stability of irinotecan injection concentrate and irinotecan infusion solutions after dilution in two commonly used infusion fluids (0.9% sodium chloride, 5% dextrose) in PVC bags, stored under refrigeration (2-8°C) or at room temperature either light protected or exposed to light. Methods. Stability of irinotecan injection concentrate was determined in the original amber glass vials. Diluted irinotecan infusion solutions were aseptically prepared by further dilution of irinotecan stock solution with either 0.9% sodium chloride or 5% dextrose in PVC bags, in amounts yielding irinotecan concentrations of 0.4, 1.0, or 2.8 mg/ml. Test solutions were s…

medicine.medical_specialtyChromatographybusiness.industryInfusion solutionSodiumchemistry.chemical_elementInjection concentrateDilutionSurgeryIrinotecan03 medical and health sciences0302 clinical medicineIrinotecan InjectionOncologychemistry030220 oncology & carcinogenesisMedicinePharmacology (medical)business030215 immunologymedicine.drugJournal of Oncology Pharmacy Practice
researchProduct

Hyperlactacidaemia in isolated hyperthermic perfusion of tumour bearing rat limbs: a study of feasibility using a novel infusion solution.

1999

In a methodological study the applicability of hyperlactacidaemia in isolated hyperthermic perfusion of tumour-bearing rat limbs was investigated.In 50 Sprague Dawley rats, DS-sarcoma growth was initiated on the right food dorsum by subcutaneous injection of 0.5 ml ascites cells. In the anaesthetized animals isolated limb perfusion was performed under steady state conditions for 60min using a miniature equipment. Thereafter tumour volume was measured daily. (a) Investigation of feasability: 40 rats were allocated to four groups. Group I: Normothermic perfusion at 38 degrees C, n = 10; Group II: Hyperthermic perfusion at 40-41 degrees C, n = 10; Group III: Normothermic perfusion at 38 degree…

HyperthermiaCancer ResearchPathologymedicine.medical_specialtyPhysiologyHyperthermic perfusionRats Sprague-DawleySubcutaneous injectionPhysiology (medical)AscitesmedicineSprague dawley ratsAnimalsImmunologic FactorsLactic AcidInfusion solutionbusiness.industryExtremitiesHyperthermia Inducedmedicine.diseaseRatsAnesthesiaChemotherapy Cancer Regional PerfusionFeasibility StudiesMethodological studyFemaleSarcoma Experimentalmedicine.symptombusinessPerfusionInternational journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
researchProduct

Physicochemical stability of human insulin 1 I.U./mL infusion solution in 50 mL polypropylene syringes

2021

Abstract Objectives The objective of this study was to investigate the physicochemical stability of human insulin 1 I.U./mL injection solutions (Insuman® Rapid) diluted with 0.9% NaCl solution in 50 mL disposable three-piece polypropylene syringes and stored refrigerated or at room temperature. Methods 1 I.U./mL test solutions were prepared with Insuman® Rapid and 0.9% sodium chloride infusion solution in 50 mL Original-Perfusor® syringes and BD® Perfusion syringes. Test solutions were stored for 90 days at 2–8 °C/dark or 48 h at 20–25 °C/diffuse room light in order to determine chemical stability. Additional test solutions were stored 28 days at 2–8 °C/dark followed by 24 h at 20–25 °C/dif…

PharmacologyPolypropyleneChromatographyInternational unitphysicochemical stabilityInfusion solutionPharmacyRM1-950polypropylene syringechemistry.chemical_compoundchemistryHuman insulinhuman insulinPharmacology (medical)intravenous injectionTherapeutics. PharmacologyHD9665-9675Pharmaceutical industryPharmaceutical Technology in Hospital Pharmacy
researchProduct

Physicochemical stability of carfilzomib (Kyprolis®) containing solutions in glass vials, ready-to-administer plastic syringes and infusion bags over…

2017

Centralized aseptic preparation of ready-to-administer carfilzomib containing parenteral solutions in plastic syringes and polyolefine (PO) infusion bags needs profound knowledge about the physicochemical stability in order to determine the beyond-use-date of the preparations. Therefore, the purpose of this study was to determine the physicochemical stability of carfilzomib solution marketed as Kyprolis® powder for solution for infusion. Reconstituted solutions and ready-to-administer preparations of Kyprolis® stored under refrigeration (2–8℃) or at room temperature (25℃) were analyzed at predetermined intervals over a maximum storage period of 28 days. Chemical stability of carfilzomib wa…

Chromatographybusiness.industryInfusion solutionPh measurementCarfilzomibVial03 medical and health scienceschemistry.chemical_compound0302 clinical medicineOncologychemistry030220 oncology & carcinogenesisMedicinePharmacology (medical)Aseptic processingbusinessParenteral solutions030215 immunologyJournal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
researchProduct

Stability of topotecan infusion solutions in polyvinylchloride bags and elastomeric portable infusion devices

1999

Purpose. The purpose of this study was to determine the physicochemical stability of topotecan after reconstitution and after further dilution in two commonly used infusion fluids (0.9% sodium chloride, 5% dextrose) in both polyvinylchloride (PVC) bags and elastomeric portable infusion devices. Methods. Each vial of topotecan (Hycamtin®) was reconstituted with sterile water for injection, yielding a nominal concentration of 1 mg/mL. Topotecan infusion solutions were aseptically prepared by further dilution of reconstituted topotecan solutions with either 0.9% sodium chloride or 5% dextrose in both PVC bags and portable elastomeric infusion devices, in amounts yielding topotecan concentrati…

endocrine system diseasesbusiness.industryInfusion solutionSodiumchemistry.chemical_elementDilution03 medical and health sciences0302 clinical medicinechemistryOncology030220 oncology & carcinogenesisAnesthesiamedicineTopotecanPharmacology (medical)business030215 immunologymedicine.drugJournal of Oncology Pharmacy Practice
researchProduct